Swiss-based Bachem is a global leader focused on one of the most attractive areas within pharma outsourcing - TIDES, comprising peptides and oligonucleotides (GLP-1 therapies and complex APIs). Protected by high technological barriers to entry, the company benefits from long-term contracts with key pharma partners which ensure a strong growth outlook but also require high capex to carry out large-scale expansion projects. At this stage, we do not see the risk/reward profile on the stock as attra...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.